{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:35:00Z","timestamp":1787726100913,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jamda.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T12:48:08Z","timestamp":1469537288000},"page":"862.e11-862.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Active Vaccines for Alzheimer Disease Treatment"],"prefix":"10.1016","volume":"17","author":[{"given":"Rosalie M.","family":"Sterner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Y.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee C.","family":"Yu Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2016.06.009_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","article-title":"Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers","volume":"88","author":"Reitz","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jamda.2016.06.009_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/imj.12572","article-title":"Dementia in older people: An update","volume":"44","author":"LoGiudice","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jamda.2016.06.009_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/gps.3946","article-title":"Survival in dementia and predictors of mortality: A review","volume":"28","author":"Todd","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2016.06.009_bib4","doi-asserted-by":"crossref","first-page":"908915","DOI":"10.1155\/2014\/908915","article-title":"Global epidemiology of dementia: Alzheimer's and vascular types","volume":"2014","author":"Rizzi","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jamda.2016.06.009_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.bcp.2014.01.003","article-title":"Future directions in Alzheimer's disease from risk factors to prevention","volume":"88","author":"Imtiaz","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jamda.2016.06.009_bib6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.arcmed.2012.11.003","article-title":"Epidemiology of dementias and Alzheimer's disease","volume":"43","author":"Sosa-Ortiz","year":"2012","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jamda.2016.06.009_bib7","series-title":"Medicines DoEDa","article-title":"Priority Medicines for Europe and the World \u201cA Public Health Approach to Innovation\u201d","author":"Kaplan","year":"2013"},{"key":"10.1016\/j.jamda.2016.06.009_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.18773\/austprescr.2015.018","article-title":"Treatment for Alzheimer's disease: Has anything changed?","volume":"38","author":"Waite","year":"2015","journal-title":"Aust Prescr"},{"key":"10.1016\/j.jamda.2016.06.009_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2741\/4285","article-title":"An update on drug treatment options of Alzheimer's disease","volume":"19","author":"Allgaier","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.jamda.2016.06.009_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1590\/1414-431X20143434","article-title":"Alzheimer's disease: Is a vaccine possible?","volume":"47","author":"Alves","year":"2014","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.jamda.2016.06.009_bib11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","article-title":"A\u00a0fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease","volume":"11","author":"Agadjanyan","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jamda.2016.06.009_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JAD-2010-1230","article-title":"A\u00a0physiological role for amyloid-beta protein: Enhancement of learning and memory","volume":"19","author":"Morley","year":"2010","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.jamda.2016.06.009_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2016.06.009_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.jamda.2016.06.009_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jamda.2016.06.009_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jamda.2016.06.009_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","article-title":"Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease","volume":"7","author":"Farlow","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.jamda.2016.06.009_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: Results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jamda.2016.06.009_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer's disease in clinical trials","volume":"68","author":"Godyn","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jamda.2016.06.009_bib20","first-page":"P282","volume":"9","author":"Arai","year":"2013","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.jamda.2016.06.009_bib21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.4161\/hv.27882","article-title":"Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines","volume":"10","author":"Davtyan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jamda.2016.06.009_bib22","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: Prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jamda.2016.06.009_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-8-36","article-title":"Immunotherapy for Alzheimer's disease: hoops and hurdles","volume":"8","author":"Lemere","year":"2013","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.jamda.2016.06.009_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","article-title":"Immunotherapeutic approaches for Alzheimer's disease","volume":"85","author":"Wisniewski","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.jamda.2016.06.009_bib25","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jamda.2016.06.009_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuroscience.2015.08.039","article-title":"The keystone of Alzheimer pathogenesis might be sought in Abeta physiology","volume":"307","author":"Puzzo","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.jamda.2016.06.009_bib27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","article-title":"Three dimensions of the amyloid hypothesis: Time, space and 'wingmen'","volume":"18","author":"Musiek","year":"2015","journal-title":"Nat Neurosci"},{"issue":"1484","key":"10.1016\/j.jamda.2016.06.009_bib28","first-page":"e1415","article-title":"Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory","volume":"33","author":"Puzzo","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jamda.2016.06.009_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2016.06.009_bib30","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/nm783","article-title":"Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease","volume":"8","author":"Hock","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jamda.2016.06.009_bib31","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awn261","article-title":"Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain","volume":"131","author":"Boche","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jamda.2016.06.009_bib32","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/brain\/awq056","article-title":"Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology","volume":"133","author":"Serrano-Pozo","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jamda.2016.06.009_bib33","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awt210","article-title":"Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization","volume":"136","author":"Zotova","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.jamda.2016.06.009_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","article-title":"Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease","volume":"14","author":"Ferrer","year":"2004","journal-title":"Brain Pathol"},{"key":"10.1016\/j.jamda.2016.06.009_bib35","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2016.06.009_bib36","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jamda.2016.06.009_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nan.12192","article-title":"Invited review: Drug development for tauopathies","volume":"41","author":"Gruninger","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.jamda.2016.06.009_bib38","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152586101630216X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152586101630216X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:15:40Z","timestamp":1761506140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152586101630216X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S152586101630216X"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2016.06.009","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Vaccines for Alzheimer Disease Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine.","name":"copyright","label":"Copyright"}]}}